ABSTRACT
Dialysis treatment is an expensive process, and, since dialysis cartridges are not manufactured in India, imported cartridges increases the treatment costs further. Each of these dialyzer cartridges costs around Rs. 1500–2000 for the end user, and a kidney failure patient typically requires around 140 such cartridges per year. Non-affordability forces patients to reuse the cartridges, which raises the risks of infection, cardiac arrest, and other complications in subsequent dialysis sessions. The technology would prove to be a commercial boon for manufacturers, as the market size is large. The South-East Asian region, with countries like the Philippines, presents tremendous potential for growth. Europe, the Middle East, and Africa together contribute 25" of dialysis patients. It is reported that around 16,000 myeloma patients are diagnosed every year in India. Hence, from the perspective of business development, this unfortunate scenario presents a huge opportunity for commercialization of the developed end-to-end technology.
